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Abstract
Background Worldwide, risk-equalization (RE) models in
competitive health insurance markets have evolved from
simple demographic models to sophisticated models con-
taining diagnosis and pharmacy-based indicators of health.
However, these models still have important imperfections;
adding information on (diagnoses of) physiotherapy treat-
ment may further improve RE-models. Therefore, a new
risk-adjuster based on physiotherapy costs in the prior year
was introduced in the Dutch RE-model of 2016.
Methods Physiotherapy claims-data (2012) and adminis-
trative data on costs and risk-characteristics (2013) for 94%
of the Dutch population (N = 15.8 million) are used to
evaluate the current risk-adjuster based on physiotherapy
costs and to assess the effects of replacing it by different
modalities of a risk-adjuster based on physiotherapy diag-
noses. Of the 89 diagnoses in the claims-data, 62 are
dropped because they relate to temporary health problems.
The 27 retained diagnoses are added to the Dutch model in
4 modalities: 27 separate risk-classes, 9 diagnosis-clusters
based on main pathology category, 4 diagnosis-clusters
based on residual costs, and the 4 clusters of modality 3
interacted with age.
Results Although the cost-based risk-adjuster improves the
model’s predictive power and removes the average
undercompensation (€919) for enrollees with physiother-
apy costs in the prior year, it is outperformed by all 4
diagnosis-based modalities. Of these modalities, modality
3 is preferred based on its simplicity and comparable pre-
dictive power.
Conclusions Adding information on physiotherapy can
further improve the performance of sophisticated RE-
models. Regarding the Dutch model, a risk-adjuster con-
taining 4 risk-classes for clustered diagnoses based on
residual costs is the preferred modality.
Keywords Health insurance  Risk equalization 
Physiotherapy diagnoses  Claims data
JEL Classification I11  I13  G22
Introduction
In an increasing number of competitive health insurance
markets, risk equalization (RE) is used as a mechanism that
provides insurers with a compensation for each enrolled
person based on expected costs and adjusted for individual
risk characteristics. As a result, insurers receive a higher
payment for high-risk enrollees (e.g. the elderly and
chronically ill) than for low-risk enrollees (e.g. the young
and healthy). In the presence of premium-rate restrictions,
the goal of RE is to reduce incentives for risk selection
while maintaining insurers’ incentives for promoting effi-
ciency of care [1].
Different forms of RE have been implemented in Europe
[2–6] and the US [7, 8]. In the last decades, RE-models
have developed from simple demographic models to
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sophisticated models using diagnosis and pharmacy-based
indicators of health [3, 4, 7, 8]. For example, the Dutch RE-
model for curative somatic care now contains about 160
risk-classes, almost half of which can be considered direct
proxies for health because they are based on diagnoses or
prior utilization related to chronic illness [4]. However,
even these sophisticated models have important imperfec-
tions and result in undercompensations for individuals with
rare diseases, (functional) disability, multi-morbidity, and
poor self-reported health. For example, the Dutch RE-
model of 2015 results in a statistically significant average
undercompensation of €378 for the subgroup of individuals
who judge their own health as ‘alright’, ‘poor’, or ‘very
poor’ (about 20% of the population) [9]. Undercompensa-
tions such as these provide insurers with incentives for risk
selection, which is undesirable because it may reduce
quality of care, efficiency of care, and solidarity between
healthy and chronically ill people [10]. Even in the pres-
ence of regulations such as open enrollment, no exclusion
of preexisting conditions, and standardized insurance
coverage, many (subtle) forms of risk selection are possible
[11].
A potentially viable option for further improving RE-
models is to make use of information on (diagnoses from)
treatments in primary care. Although current sophisticated
RE-models make extensive use of diagnosis information,
this information is typically only related to specific hospital
treatments [3, 4, 7, 8]. With this in mind, several
improvements have been proposed for the Dutch RE-
model, one of which is a risk-adjuster based on the prior
use of physiotherapy [9]. The rationale of this adjuster is
threefold. First, the RE-model 2015 results in an average
undercompensation of about €1000 for the subgroup of
almost 400,000 adults with physiotherapy costs under the
basic insurance in the prior year [12]. Second, under the
Dutch basic insurance, coverage for physiotherapy for
adults starts at the 21st reatment (provided there is a
referral from a physician who sets the diagnosis) and is
limited to specific chronic conditions (see table, supple-
mental digital content 1). For individuals age 17 and
younger, all treatments related to these conditions are
covered, in addition to a maximum of 18 treatments for
other conditions. Thus, a risk-adjuster based on the use of
physiotherapy could potentially reduce undercompensa-
tions for chronically ill people. Finally, medical experts
indicated that undercompensated groups of people with
rare genetic diseases often make use of physiotherapy.
Therefore, a dummy-variable for yes/no physiotherapy
costs in the prior year was added to the Dutch RE-model
2016 under the name ‘physiotherapy utilization groups’
(PUGs). For practical reasons (e.g. the difference in cover-
age), the PUGs only apply to adults. Although the PUGs
removed the undercompensation for the subgroup with
physiotherapy costs in the prior year, this risk-adjuster has
several disadvantages [12]. First, since it is based on prior
costs, it is ‘endogenous’ and reduces insurers’ incentives for
promoting efficiency of care. Second, in the prior year’s cost-
data it is not possible to distinguish between ‘permanent’
chronic conditions for which coverage exists regardless of
the duration of the treatment, and ‘temporary’ conditions
covered for a limited treatment duration only (see table,
supplemental digital content 1). In RE, however, risk-ad-
justers ideally relate only to chronic conditions (not to tem-
porary health problems) because the aim is to compensate
insurers for predictable cost variation. Third, as the risk-
adjuster is only based on yes/no costs in the prior year, it does
not take the severity of the underlying diagnosis into account.
Finally, the specific characteristics of the prior year’s cost
data preclude inclusion of children in the risk-adjuster.
These problems may be overcome by using information
on diagnoses of physiotherapy treatment (instead of on
prior costs) [12]. The resulting adjuster would be a more
direct proxy for health and similar to the diagnosis-based
cost groups (DCGs) in the Dutch RE-model, in which
enrollees are classified into risk-classes using diagnoses
from hospital treatments [13, 14]. At the time the PUGs
were developed, data on physiotherapy diagnoses were not
available for research purposes. However, at the end of
2015, when a new research cycle for improving the RE-
model of 2016 started, these data came available.
In this paper, using physiotherapy claims data of 2012
and administrative data on costs and risk characteristics of
2013 for (almost) the entire Dutch population, we evaluate
the PUGs and assess the effects of replacing the PUGs by
different modalities of an alternative risk-adjuster labeled
‘physiotherapy-diagnosis groups’ (PDGs). Specifically, our
goal is threefold: (1) to study the possibilities of improving
RE using information on (the use of) physiotherapy (2) to
develop different modalities of a risk-adjuster based on
physiotherapy diagnoses and (3) to assess the effects of
replacing the PUGs by these modalities in terms of key
criteria for adequate risk-adjusters, including predictive
power, validity, and stability [1].
The Dutch basic health insurance system
Since 2006, Dutch residents have been obliged to purchase
basic health insurance coverage for a standardized benefits
package. In 2016, this basic insurance scheme comprises
about 70% of total healthcare spending and is characterized
by a form of managed competition in which insurers
compete on price and quality and enrollees can switch
annually among insurers. The scheme comprises three
main financial streams: a community-rated premium from
adult enrollees to insurers, an income-related contribution
from enrollees to the RE-fund (a national account from
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which the RE-payments to insurers are financed), and RE-
payments between insurers and the RE-fund. The RE-
payments are based on the expected costs of insurers’
enrollees in year t, which are based on the coefficients of an
OLS-regression of costs on risk characteristics using data
from t-3 (see table, supplemental digital content 2, for the
coefficients of the Dutch RE-model of 2016 with and
without the PUGs).
The Dutch RE-model 2016 contains the following ten
risk-adjusters: age/gender (40 risk-classes), region (10 risk-
classes based on clusters of zip-codes), socioeconomic status
(17 risk-classes based mainly on income, interacted with
age), source of income (24 risk-classes for self-employed,
students, higher-educated, and people with social security
benefits; interacted with age), pharmacy-based cost groups
(PCGs, 30 risk-classes based on prior use of medication
prescribed for chronic illnesses), DCGs (15 risk-classes
based on diagnoses from hospital treatments in the prior
year), durable medical equipment cost groups (DMECGs, 4
risk-classes based on prior use of durable medical equip-
ment), multi-year high cost groups (MYHCGs, 6 risk-classes
based on high costs in the prior 3 years), PUGs (1 risk-
class), and 4 interaction risk-classes. In this model, the
PCGs, DCGs, DMECGs and MYHCGs can be considered as
‘morbidity-based’ and thus as direct proxies for health.
In addition, the model contains 2 risk-adjusters based on
the costs of home care and of geriatric revalidation in the
prior year. However, both adjusters are excluded here
because (1) the Dutch Minister of Health aims to abolish
these ‘endogenous’ risk-adjusters ultimately by the end of
2018 [15] and (2) these adjusters may have confounding
effects on the results.
Methods
Two main datasets are used for this study. First, we use a
dataset containing all basic health insurance claims
(N = 14.4 million) for physiotherapy treatments provided
to about 700,000 patients in 2012. Importantly, the claims
contain a diagnosis-code based on a classification system
that enables the physiotherapist to register the body-loca-
tion and the pathology of the diagnosis using a 4-digit
coding. Digits 3 and 4 refer to the pathology, with digit 3
being the main category (e.g. neurological condition) and
digit 4 the subcategory (e.g. paraplegia). For this study,
only digits 3 and 4 (henceforth: diagnosis) are relevant
because for a given pathology, it is highly unlikely that a
difference in body-location involves a difference in health.
In total, 89 different diagnoses can be discerned in the
claims data.
The second dataset contains administrative, individual-
level data on costs and risk characteristics in 2013 for the
entire Dutch population (N = 16.9 million). This dataset
was actually used for calculating the RE-payments for
Dutch insurers for 2016, and came from various adminis-
trative sources. Costs comprise the total costs for curative
somatic care under the basic health insurance of 2016
(cost-level 2013). As is customary in the Dutch RE-model,
costs of enrollees were annualized and weighted for each
enrollee for the duration of the insurance contract in 2013.
Given these datasets, we used a 7-step procedure to
address the research objectives:
1. Delete unusable/incorrect claims. We deleted physio-
therapy claims with an unknown diagnosis-code and/or
a negative claim-amount. In addition, we deleted
clearly invalid claims (e.g. child physiotherapy claims
submitted for adults) and all claims pertaining to the
enrollees of 3 insurers because these insurers submitted
incomplete or no claims. As a result of these
selections, the number of patients with a physiotherapy
diagnosis reduced to approximately 675,000.
2. Merge the cleaned claims data with the administrative
data. Using a unique (anonymous) identification key,
we merged the 2012 claims data with the 2013
administrative data on the individual enrollee-level.
As a result of the first step, the number of enrollees in
the administrative data reduced from 16.9 million to
15.8 million.
3. Estimate the Dutch RE-model 2016 by OLS using
2013-costs as the dependent variable and the above
mentioned risk-adjusters excluding the PUGs as the
explanatory variables, and calculate the predicted costs
for each enrollee (see table, supplemental digital
content 2, for the coefficients of this model).
4. Calculate the mean (residual) costs for each of the 89
diagnoses (see table, supplemental digital content 3).
Mean residual costs are calculated by subtracting for
each enrollee the predicted costs from the actual costs
and averaging the result to the diagnosis-level.
5. Delete diagnoses related to temporary health problems.
Sixty-two diagnoses related to conditions not covered
for adults (e.g. respiratory infections) and/or to condi-
tions with limited treatment duration (e.g. fractures)
were dropped. These diagnoses have a relatively low
prevalence and/or low residual costs (see table, sup-
plemental digital content 3), implying limited predic-
tive power compared to the 27 retained diagnoses. In
this step, we were assisted by a team of medical
professionals, experts from health insurance compa-
nies, and experts from the Dutch Ministry of Health.
6. Construct 4 PDG-modalities based on the retained 27
diagnoses: (1) the 27 diagnoses as separate risk-classes
(2) the diagnoses clustered in 9 risk-classes based on
main pathology category (3) the diagnoses clustered in
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4 risk-classes based on residual costs, and (4) the 4
risk-classes from modality 3 interacted with age (0–17,
18–64, 65?). For modality 3, diagnoses were sorted on
descending residual costs, in such a way that patients
with multiple diagnoses are classified in the applicable
diagnosis with the highest residual costs. Using Ward’s
hierarchical clustering method [16], diagnoses were
then clustered into 4 mutually exclusive groups based
on homogeneity in residual costs, taking into account
the diagnoses’ standard deviation and prevalence and
in such a way that the differences among the diagnosis-
clusters in mean residual costs is maximized. The
rationale for modality 4 is that research shows that age
may play a role when predicting healthcare costs using
information on physiotherapy utilization [12].
7. Estimate (by OLS) 5 additional versions of the Dutch
RE-model of 2016 and compare the results. These
versions are the RE-model 2016 with the current PUGs
and the RE-model 2016 with the PUGs replaced by 1
of the 4 PDG-modalities.
Assisted by a team of medical professionals and experts
from health insurance companies, we assessed the validity
of the 2012 claims data using (1) administrative data on
individual-level costs for different types of primary care
(including physiotherapy) for 2012 and 2013, and (2)
physiotherapy claims data of 2013. Based on additional
analyses on these data (see figures, supplemental digital
content 4), the validity could be confirmed and did not lead
to any further modifications or selections.
Results
Descriptive statistics
Table 1 shows descriptive statistics for all enrollees, for
enrollees with physiotherapy costs in 2012, and for three
groups of enrollees with a physiotherapy diagnosis in 2012.
For (adult) enrollees with physiotherapy costs in 2012, total
costs are on average €908 higher than for enrollees (of all
ages) with at least 1 of the 27 diagnoses in 2012. However,
residual costs are €434 higher in the latter group, which is
particularly notable in view of the €238 lower residual
costs for enrollees (of all ages) with at least 1 of the 89
original diagnoses as compared to enrollees with physio-
therapy costs in 2012.
The bottom row of Table 1 shows that almost 52% of
enrollees with the 27 diagnoses are classified into one or
more risk-classes of the current ‘morbidity-based’ risk-
adjusters. This implies that any version of a risk-adjuster
based on the 27 diagnoses will show considerable overlap
with these risk-adjusters. This overlap, however, is sub-
stantially less compared to the current PUGs (see also
table, supplemental digital content 5).
As a result of dropping 62 diagnoses, the (weighted)
number of patients with at least 1 diagnosis decreased from
664,139 to 286,342. As shown in the last two columns of
Table 1, mean residual costs for the dropped diagnoses are
almost eight times lower than for the 27 retained diagnoses.
Thus, the dropped diagnoses either have a low prevalence,
Table 1 Descriptive statistics for the year 2013
All enrollees in
merged dataset
Enrollees with physiotherapy
costs in 2012 (i.e. PUG[ 0)
Enrollees with
C1 of 89 original
diagnoses in
2012
Enrollees with
C1 of 62 dropped
diagnoses in 2012
Enrollees with
C1 of 27 selected
diagnoses in 2012
Included age groups All ages Ages 18? only All ages All ages All ages
N (weighted)a 15,523,485 312,282 664,139 377,797 286,342
Costs in € [mean (st. dev.)] 2162 [7927] 8836 [17,065] 5155 [14,099] 3054 [8702] 7928 [18,645]
Residual in € [mean
(st. dev.)]b
0 [6850] 919 [14,496] 681 [11,708] 172 [7312] 1353 [15,704]
Age (mean) 40.8 61.0 34.7 33.9 35.9
Men (%) 49.3 37.2 45.4 42.6 49.1
Classified in a PCG (%) 19.6 55.6 28.9 21.8 38.4
Classified in a DCG (%) 9.4 41.8 22.2 17.3 28.7
Classified in a DMECG (%) 0.9 5.4 2.8 1.5 4.5
Classified in a MYHCG (%) 5.9 47.7 24.7 15.6 36.6
Classified in a PCG, DCG,
DMECG, or MYHCG (%)
24.6 73.9 40.6 32.1 51.8
a N = the number of enrollees weighted by the duration of enrollment in 2013
b Residual costs based on Dutch RE-model 2016 without the PUGs as a risk adjuster. Because the model is estimated by OLS, the average
residual for all enrollees equals 0 (by definition)
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low residual costs, or both, confirming the adequacy of
basing the PDG-modalities on the 27 diagnoses.
Stability over time
Ideally, the prevalence of a risk-adjuster is stable at the
individual insurer-level; large fluctuations over time may
indicate problems or differences in claims registration
among insurers [1]. Figure 1 shows the prevalence of the
27 diagnoses and the PUGs, respectively, at the level of the
23 insurers, for 2 years. Figure 1 indicates that a risk-ad-
juster based on the 27 diagnoses will be more stable at the
insurer-level than the PUGs (based on physiotherapy
costs). In panel a, the mean absolute change from 2012 to
2013 is 0.28 per 1000 patients. In panel b, this is 1.17,
while the overall prevalence is only 9% higher compared to
panel A.
In an additional analysis, we examined the changes in
prevalence at the diagnosis-level (see figure, supplemental
digital content 6). The changes are very small, especially in
comparison to the common year-to-year changes in the
prevalence of the current PCGs and DCGs [17].
PDG-modalities
Table 2 presents information for the PUGs and for 3 of the
4 PDG-modalities (for clarity of presentation, modality 4 is
excluded in this table). For modality 1 and 2, summation of
the (weighted) number of patients yields 289,375, about
3000 more than the 286,342 patients in Table 1. This
means that only 1% of enrollees have multiple diagnoses,
so classifying enrollees in the diagnosis with the highest
residual costs, as done in all modalities when estimating
the coefficients, will have very limited consequences for
the predictive power.
In modality 1, residual costs vary from €352 to €22,730.
The estimated coefficients are on average approximately
€250 higher than the residual costs, which means that these
risk-classes take over some of the predictive power of the
other risk-adjusters in the model. The variation in coefficients
for modality 2 is much smaller as compared to modality 1.
The (residual) costs and thus the coefficients of the
clusters of modality 3 sharply increase as the cluster
number goes up. An additional analysis shows that the
clusters explain 94% of the variance in residual costs
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Fig. 1 Number of patients per 1000 with at least one of 27 physiotherapy diagnoses (panel a) or with physiotherapy costs (panel b) for 23 risk-
bearing insurers, for 2 years. In both panels, the numbers for the year 2012 are adjusted for the overall change in prevalence from 2012 to 2013
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Table 2 Key statistics for three PDG-modalities for the year 2013 (costs and coefficients in €)
Code/cluster Description Na Mean
costs
Mean residual
costsb
Estimated
coefficientc
PUG
Physiotherapy costs in 2012 312,282 8836 919 1008
PDG-modality 1
Code 00 Amputation 2536 15,603 1737 1971
Code 10 Aseptic bone necrosis 375 1377 354ns 423
Code 11 Disorders of the vertebral column/pelvis 19,344 2333 355 435
Code 12 Congenital disorders of the skeleton 5895 5250 1235 1334
Code 13 Ossification disorder 1107 4311 473 567
Code 14 Inflammation of/tumors in the skeleton 676 16,476 5948 6125
Code 28 Sudeck’ a(dys)trophy 4692 8351 1043 1173
Code 39 Status after burn wounds 149 7063 1732 1889
Code 46 Disorders of the lymphatic system/edema 21,578 9120 399 471
Code 51 Congenital disorders of respiratory system 566 35,374 11,253 12 049
Code 54 Chronic obstructive pulmonary disease 23,308 14,470 1840 2117
Code 56 Interstitial lung disorder including sarcoı¨dosis 920 14,792 3767 3534
Code 65 Other hereditary disorders 460 35,808 22,767 23,014
Code 69 Tumors without surgery 3273 17,060 1915 2058
Code 70 Peripheral nerve disorder 6404 9791 1819 1918
Code 71 Cerebellar disorders 6755 11,562 1068 1281
Code 72 Cerebrovascular accident/central paresis 27,049 13,049 2566 2773
Code 73 MS/ALS/spinal muscle atrophy 9037 17,831 3069 3692
Code 74 Parkinson’s disease/extrapyramidal disorder 15,077 14,063 1474 2408
Code 76 Paraplegia, including traumatic and partial 2553 25,125 2455 3220
Code 77 Neurotraumata 2272 8166 1609 1765
Code 78 Other neurological disorders 12,171 15,652 3820 4089
Code 79 Psychomotor retardation/development disorders 117,681 2607 738 832
Code 94 Other collagen disorders 4219 9252 1800 1782
Code 95 Scar tissue 239 8642 1701ns 1897
Code 96 Scleroderma 502 16,505 2078 2334
Code 99 Other skin disorders 537 8354 472ns 657
PDG-modality 2
Code 0x Surgery, musculoskeletal system 2536 15,773 1820 1924
Code 1x Orthopedic disorders without surgery 27,234 3387 689 858
Code 2x Surmenage, degenerative disorders, dystrophy 4692 8392 1054 1151
Code 3x Traumatic disorders excl. surgery/neurotraumata/paraplegia 149 7254 1896 1910
Code 4x Disorders of heart/veins/lymphatic system incl. cardio
surgery
21,578 9146 386 469
Code 5x Lung disorders 24,769 14,984 2098 2343
Code 6x Other internal disorders excl. surgery/musculoskeletal
system
3733 19,393 4432 4641
Code 7x Neurological disorders 198,031 7267 1401 1654
Code 9x Collagen disorders and skin disorders 5494 9840 1699 1709
PDG-modality 3
Cluster 1 Included diagnoses: 10, 11, 12, 13, 28, 46, 71, 79, 99 175,508 3859 661 779
Cluster 2 Included diagnoses: 0, 39, 54, 69, 70, 74, 77, 94, 95 57,039 13,414 1715 2095
Cluster 3 Included diagnoses: 14, 56, 72, 73, 76, 78, 96 52,770 15,223 2984 3295
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among the 27 diagnoses, implying almost no information
loss as a result of the clustering. Compared to modality 2,
the (residual) cost variation is much better captured, as
becomes clear from the variation in coefficients.
In modality 4, over 75% of the patients classified in the
first cluster are below age 18, while the 3 other clusters
consist for 95% of adult patients (data not shown). This
implies that if the RE-model includes modality 1, 3 or 4,
the substantial residual-cost differential between children
and adults with a physiotherapy diagnosis (i.e. €770 versus
€1936) is already accounted for. Within the clusters, the
coefficients vary by age (see supplemental digital content
2), but this has limited meaning when the prevalence per
risk-class is taken into account.
Finally, the fit statistics in Table 3 imply that while all
PDG-modalities (slightly) outperform the PUGs in terms of
predictive power, modality 3 is preferred over the other
modalities in view of its equal or better fit and the lowest
number of risk-classes.
Discussion and conclusion
Although RE-models in competitive health insurance
markets have become increasingly sophisticated, they often
still result in substantial undercompensations for specific
groups of people in poor health. A potentially viable option
to further improve RE-models is to make use of informa-
tion on (diagnoses of) treatments in primary care instead of
only hospital care (as is common in current RE-models
[3, 4, 7, 8]). Hence, a new risk-adjuster based on the prior
use of physiotherapy (‘physiotherapy utilization groups’,
PUGs) was introduced in the Dutch RE-model of 2016.
However, this risk-adjuster has clear disadvantages since it
is based on prior costs and does not take the severity of the
underlying diagnosis into account.
Using physiotherapy claims data of 2012 and administra-
tive data on costs and risk characteristics of 2013 for almost
the entire Dutch population, this paper investigated the pos-
sibilities of improving RE using information on (use of)
physiotherapy by (1) evaluating the current cost-based PUGs
and (2) assessing the effects of replacing this risk-adjuster by
4 different modalities of an alternative risk-adjuster based on
27 physiotherapy diagnoses related to specific chronic con-
ditions (‘physiotherapy diagnosis groups’, PDGs).
Although adding the PUGs removes the average
undercompensation of €919 for the subgroup of enrollees
with physiotherapy costs in the prior year and (slightly)
improves the model’s predictive power, all 4 PDG-
modalities have clear advantages over the PUGs in terms of
validity, stability, measurability, incentives for efficiency,
predictive power, and simplicity/transparency.
Table 2 continued
Code/cluster Description Na Mean
costs
Mean residual
costsb
Estimated
coefficientc
Cluster 4 Included diagnoses: 51, 65 1025 35,571 16,340 17,056
a N = the number of patients weighted by the duration of enrollment in 2013. For PDG-modality 1 and 2, enrollees may be classified in more
than one diagnosis. For PDG-modality 3, enrollees are classified in the cluster containing the applicable diagnosis with the highest residual costs
b Residual costs based on the RE-model of 2016 without the PUGs as a risk-adjuster. The subscript ‘ns’ indicates that the residual is not
statistically significant different from 0 at a significance level of 1%
c Coefficient based on the RE-model of 2016 with the PUGs or with the PUGs replaced by PDG-modality 1, 2 or 3. For all PDG-modalities,
enrollees are classified in the applicable diagnosis with the highest residual costs. All coefficients are statistically significant different from 0 a
significance level of 1%
Table 3 Fit statistics on the
individual-level for five
versions of the Dutch RE-model
of 2016
Model R2 9 100%a CPM 9 100%b MAPEc
RE-model 2016 without PUGs 25.33 27.19 1976.54
RE-model 2016 with PUGs 25.36 27.28 1973.97
RE-model 2016 without PUGs ? PDG-modality 1 25.45 27.32 1972.83
RE-model 2016 without PUGs ? PDG-modality 2 25.41 27.28 1973.95
RE-model 2016 without PUGs ? PDG-modality 3 25.45 27.33 1972.78
RE-model 2016 without PUGs ? PDG-modality 4 25.45 27.33 1972.69
a R2 = proportion explained variance = 1-(sum of squared residuals/total sum of squared differences)
b CPM = Cummings’ prediction measure = 1-(sum of absolute residuals/total sum of absolute
differences)
c MAPE = mean absolute prediction error = sum of absolute residuals divided by the weighted number
of patients
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The PDG-modalities are more valid indicators of health
than the PUGs because (1) they are based on diagnoses
instead of on costs, (2) only diagnoses pertaining to chronic
conditions are included instead of also temporary health
problems, (3) they take the severity of the underlying
diagnoses into account, and (4) all ages are included
instead of adults only.
In addition, insurers’ efficiency incentives are not
reduced since the PDG-modalities are not based on prior
costs. On the other hand, an inherent disadvantage of using
diagnosis-based risk-adjusters is that it may provide
incentives for insurers to promote classifying patients into
more ‘severe’ diagnoses-categories than is medically nec-
essary because these diagnoses are associated with higher
payment. However, while in general such upcoding prac-
tices can be a significant problem in diagnosis-based pay-
ment schemes, it is unlikely to be very relevant in the
context of this study. First, physiotherapy treatment for
adults for the conditions related to the 89 analyzed diag-
noses is not covered under the Dutch basic health insurance
until the 21st treatment. Although for children coverage
does start at the first treatment, the estimated coefficients
for the diagnoses that are most relevant for this group are
relatively low (i.e. the average coefficient for these diag-
noses is lower than that of the current PUGs), mitigating
possible upcoding incentives. More importantly, the Dutch
physiotherapy diagnosis classification system contains only
89 different and clearly distinct (pathology) categories. Of
these, only 27 are relevant for the PDG-modalities, which
all pertain to serious ‘permanent’ chronic conditions for
which upcoding does not seem to be a real issue. Still,
although we thus believe there to be limited potential for
upcoding in this context, as with any diagnosis-based
payment scheme, monitoring changes in diagnosis preva-
lence over time as well as periodic validation of set diag-
noses (e.g. by contrasting diagnosis prevalence patterns
with utilization patterns of related types of care) is
advisable.
Regarding measurability, the advantage of the PDG-
modalities is that no arbitrary decisions are required for
determining when someone will be classified in the risk-
adjuster or not. In the current RE-model, enrollees are
classified in a PUG[ 0 if their physiotherapy costs in the
prior year are in the top-2%. Although this threshold was
introduced to eliminate the impact of administrative (data)
flaws and to mitigate the reduction in efficiency incentives,
it was arbitrarily determined. On the other hand, in con-
structing the PDG-modalities the enrollees of three insurers
were necessarily dropped because of lacking or inadequate
claims. However, this problem appears to have been solved
in the 2013-claims data.
Regarding stability, this paper has shown that in terms
of the number of patients classified, the PDGs are more
stable at the insurer-level than the PUGs. In addition, the
prevalence of the 27 diagnoses varies only marginally over
time. Although our data did not permit analysis of the
stability of coefficients, findings from the recent annual
update of the RE-model confirm that the (pattern in the)
coefficients of PDG-modality 3 (i.e. the 27 diagnoses
clustered in 4 risk-classes based on residual costs) are
indeed stable [18]: the weighted average absolute change in
estimated coefficients from 2013 to 2014 equals €2.
Relative to the PUGs, all PDG-modalities (slightly)
improve the model’s predictive power. In turn, modality 3
outperforms the other modalities given its low number of
risk-classes and comparable or better predictive power.
Finally, all PDG-modalities are arguably more trans-
parent than the PUGs because (1) they show considerably
less overlap with the ‘morbidity-based’ adjusters already in
the model, and (2) ‘diagnoses’ are more salient and easier
to interpret than ‘costs’. Of the 4 modalities, modality 3
may be viewed as being the simplest because it consists of
only 4 risk-classes. However, as a result of the clustering
method these risk-classes have lost their (pathology) label
and thus are not clinically recognizable, reducing the
transparency. On the other hand, modality 3 is based on the
same clustering method as the current DCGs [14],
enhancing model consistency.
Our findings must be viewed in the light of three limi-
tations. First, about 1 million enrollees of three insurers
were necessarily dropped from the analysis due to inade-
quate information on physiotherapy claims of 2012.
Nonetheless, analysis was possible for 94% of the Dutch
population. Second, our data did not permit analysis of the
stability of the coefficients of the PDG-modalities. How-
ever, findings of follow-up research indicate that the
coefficients of modality 3 are indeed stable [18]. Finally,
both the 2012 and the 2013 data contain claims that are
actually not covered under the basic health insurance.
However, these claims (which were excluded from the
analysis) comprise less than 2% of the total number of
claims in both years.
In conclusion, adding information on physiotherapy
(diagnoses) can further improve the performance of already
sophisticated RE-models. Of the different physiotherapy-
based risk-adjuster modalities analyzed in this paper, the
modality based on clustered physiotherapy diagnoses based
on residual costs is the preferred modality. Compared to a
risk-adjuster based on prior physiotherapy costs, such a
diagnosis-based risk-adjuster is more valid, more stable,
more easily measured, more transparent, has more predic-
tive power, and does not compromise insurers’ incentives
for promoting efficiency of care.
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